Cardiac
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF).
- Study ID: Elevate-HF
- Principal Investigator: Puvanalingam Ayyadurai, MD, FACC
An international, multicenter, randomized, double-blind, placebo-controlled trial
evaluating the effect of in-hospital initiation of dapagliflozin in patients stabilized
during hospitalization for acute heart failure, with a focus on cardiovascular death
and worsening heart failure.
- Study ID: DAPA ACT HF-TIMI 68
- Principal Investigator: Puvanalingam Ayyadurai, MD, FACC
- Status: Not seeking patients
A randomized, double-blind, placebo-controlled trial assessing the impact of
inclisiran on major adverse cardiovascular events in participants with established
cardiovascular disease.
- Study ID: VICTORION-2 PREVENT (Novartis V2P)
- Principal Investigator: Puvanalingam Ayyadurai, MD, FACC
- Status: Not seeking patients
A randomized, double-blind, placebo-controlled, multicenter study evaluating
inclisiran for the prevention of major adverse cardiovascular events in high-risk
primary prevention patients.
- Study ID: VICTORION-1 PREVENT (Novartis V1P)
- Principal Investigator: Puvanalingam Ayyadurai, MD, FACC
- Status: Not seeking patients
A Phase 3, randomized, placebo-controlled study evaluating the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in participants at high cardiovascular risk.
- Study ID: CORALreef Outcomes — MK-0616-015
- Principal Investigator: Puvanalingam Ayyadurai, MD, FACC
- Status: Not seeking patients
Oncology
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cance Whose Tumors Express PD-L1
- Study ID: ARTEMIDE-Lung02
- Principal Investigator: Ivan Bustillo, M.D.
A Phase III Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completel Resected High-Risk Stage I Non-Small Cell Lung Cancer
- Study ID: INTerpath-014
- Principal Investigator: Ivan Bustillo, M.D.
Gynecologic
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Study ID: ECHO
- Principal Investigator: Collette Lessard, MD
- Status: Enrolling
